US Bancorp’s aTyr Pharma ATYR Stock Holding History

US Bancorp’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-316	Closed	-$228	–	4220
2025 Q3	$228	Buy	+316	New	+$1.43K	﹤0.01%	3936

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

US Bancorp's ATYR Position: Q4 2025 in Review

US Bancorp sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 316 shares — an estimated $228 sold.

US Bancorp first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $228 in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

US Bancorp reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
US Bancorp sold 316 aTyr Pharma shares in Q4 2025, an estimated $228.
US Bancorp first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
US Bancorp's aTyr Pharma position peaked at $228 in Q3 2025.
84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.